Wang Xinghuan, male (1965- ), MD, chief physician, professor (level 2), doctoral supervisor, chief expert of the National 13th Five-Year Plan Key Special Project (4 items), winner of the second prize of the National Technological Invention Award (the first completer), young and middle-aged experts with outstanding contributions to national health and family planning, Luojia Outstanding Scholar of the "351 Talent Program" of Wuhan University, the first and second medical leading talents of Hubei Province, and an expert enjoying special allowances from the State Council. He is currently the President of Zhongnan Hospital of Wuhan University, the leader of the Department of Urology and Evidence-based and Translational Medicine, and the Secretary of the Party Committee and President of Wuhan Leishenshan Hospital. He is also the director of the Center for Evidence-based and Translational Medicine of Wuhan University, the director of the Institute of Urology of Wuhan University, the director of the Hubei Provincial Human Genetic Resources Preservation Center, the director of the Hubei Provincial Engineering Research Center for Tumor Precision Diagnosis and Treatment Technology and Translational Medicine, the director of the Hubei Provincial Laparoscopic Urology Quality Control Center, and the director of the Hubei Provincial Laparoscopic Urology Clinical Medical Research Center.

Academic positions: He is currently the executive director of the Chinese Association of Research Hospitals, the chairman (founder) of the Urology Professional Committee of the Chinese Association of Research Hospitals, the director of the China Association for the Promotion of International Exchange in Health Care, the director of the Council of the Huaxia Medical Award, the chairman (founder) of the Evidence-based Medicine Branch of the China Association for the Promotion of International Exchange in Health Care, the member of the Urology Branch of the Chinese Medical Association, and the standing member of the Urology Branch of the Chinese Medical Doctor Association. Editor-in-chief of Journal of Modern Urology and New Medicine, deputy editor-in-chief of Chinese Journal of Clinicians (Electronic Edition) and Chinese Research Hospitals, and editorial board member of National Medical Journal of China. He used to be a member of the 7th and 8th Standing Committee of the Urology Branch of the Chinese Medical Association, a standing member of the Urogenital Tumor Committee of the Chinese Anti-Cancer Association, the chairman of the Andrology Branch of the Hubei Medical Association, the chairman of the Urogenital Tumor Committee of the Hubei Anti-Cancer Association, and the vice chairman of the Urology Branch of the Hubei Medical Association.

Scientific research awards: He has undertaken more than 10 national, provincial and ministerial projects, with a personal fund of more than 40 million yuan; he took the lead in formulating more than 20 national industry standards; more than 10 invention patents. He has published more than 200 papers, and many papers have been cited as evidence by international guidelines in Europe and the United States. He has published more than 10 textbooks and monographs, such as "Methodology for Evidence-Based Clinical Practice Guidellines Development and Evaluation", "Guidelines for the Diagnosis and Treatment of Benign Prostatic Hyperplasia in China", "History of Urology in China", "Wu Jieping Urology", "Huang Jiasi Surgery", and "Urology", a postgraduate textbook. He has successively won the second prize of the National Technological Invention Award (the first completer), the first prize of Hubei Provincial Science and Technology Progress Award (the first completer), the 2013 Medical Outstanding Contribution Award of the Medical Center of Wuhan University, and the second prize of the former Ministry of Health Science and Technology Progress Award.

Clinical services: He has long been committed to applying the latest technology of urology to clinical practice, and has carried out and improved a large number of minimally invasive surgeries, especially in the field of laparoscopic minimally invasive technology and transurethral plasma resection of the prostate, which has high attainments, and is internationally renowned and leading in China. He has been to the United States, France, Japan and other countries for study and exchange, and was sent to the University of Southern California Norris Hospital to study as a candidate for the "Talent Project" of the Urology Branch of the Chinese Medical Association. As a "National Key Clinical Construction Specialty (2012)" and "Hubei Provincial Urology Laparoscopic Technology Quality Control Center", the comprehensive strength of the specialty ranks among the best in China. The advanced training of laparoscopic urology (a national continuing education program) is called the "Whampoa Military Academy" of laparoscopic surgery by grassroots hospitals, and the 3D surgery at the training course has received the attention and report of CCTV.